Seres Therapeutics Inc (MCRB) Receives $23.20 Average PT from Brokerages
- Author: Zachary Reyes Mar 21, 2017,
Mar 21, 2017, 6:18
All the 6 analysts polled in the past 12 months rate Seres stock a Buy. Finally, Canaccord Genuity reiterated a "buy" rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Tuesday, January 31st.
Seres Therapeutics (NASDAQ:MCRB) opened at 12.04 on Monday.
Seres Therapeutics Inc (NASDAQ:MCRB)'s share price shot up 3.3% on Friday following a better than expected earnings announcement. The average twelve-month price target among analysts that have updated their coverage on the stock in the previous year is $23.20. Zacks Investment Research cut shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, January 11th. Now the stock price is moving -65.62% off from the highest level of twelve months and +53.67% above from twelve months low.
Currently, the company has SMA200 (200-day simple moving average) of -15.51 Percent. The company has a Low Price Target of $44 and the Mean Target of $51.71, according to the Brokers.
The Stock now has the market capitalization of $515.64 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 9.83% and monthly volatility of 5.48% respectively. (NASDAQ:MCRB) is performing 28.38%.
When Seres, the first publicly held microbiome-focused company, had a major clinical trial failure last summer for its fecal transplant aiming to treat recurrent C. diff. infection, the company's stock fell dramatically Conversely, its shares skyrocketed March 16 after the company reported fourth-quarter revenue that topped estimates, filed for a mixed-shelf offering of up to $150 million, and revealed plans to initiate the new mid-stage study for SER-109.
Many Analysts provided their foresight on Revenue Estimates of Seres Therapeutics, Inc. where they believe that the company has the potential to earn average revenue of $2.85 Million for the current quarter. The firm's market cap is $485.87 million. Investors might also notice that three month ago the Buy recommendations (6) outnumbered Sell recommendations (0). ACI Worldwide, Inc. (NASDAQ:ACIW) quarterly performance is 24.48% while its year to date (YTD) performance is 25.51%. Ellington Management Group LLC acquired a new stake in Seres Therapeutics during the fourth quarter worth about $107,000. On average, equities research analysts expect that Seres Therapeutics will post ($2.40) EPS for the current year. Renaissance Technologies LLC raised its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Finally, Trexquant Investment LP raised its stake in shares of Seres Therapeutics by 147.5% in the fourth quarter.
"Following the completion of our comprehensive analyses of the SER-109 study results, we had very productive discussions with the FDA, in which we gained highly positive and constructive guidance on further SER-109 clinical development", Seres Therapeutics chairman and chief executive officer, Roger Pomerantz, said. "Our prior SER-109 studies provided important new biological and clinical data that have advanced our pioneering microbiome therapeutic efforts". The increase in R&D expense was primarily due to expenses related to the company's microbiome therapeutics platform, the clinical development of SER-109, SER-262 and SER-287, as well as the company's preclinical programs.